[DRNA] Dicerna Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 65.71 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 3.2 Change: 0.15 (4.92%)
Ext. hours: Change: 0 (0%)

chart DRNA

Refresh chart

Strongest Trends Summary For DRNA

DRNA is in the medium-term down -25% below S&P in 2 months and down -33% in 7 months. In the long-term up 238% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company?s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Ki

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding20.73 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.76 Price/Cash Per Share0.75
Price/Free Cash Flow-1.79 ROA-55.23% ROE-59.06% ROI
Current Ratio14.81 Quick Ratio Long Term Debt/Equity Debt Ratio0.07
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities150 K Cash From Investing Activities7.07 M Cash From Operating Activities-10.65 M Gross Profit
Net Profit-14.08 M Operating Profit-14.14 M Total Assets92.75 M Total Current Assets89.09 M
Total Current Liabilities6.02 M Total Debt Total Liabilities6.02 M Total Revenue
Technical Data
High 52 week17.69 Low 52 week8.9 Last close10.37 Last change-4.07%
RSI43.69 Average true range0.7 Beta1.5 Volume169.43 K
Simple moving average 20 days-2.46% Simple moving average 50 days-11.4% Simple moving average 200 days-22.25%
Performance Data
Performance Week5.07% Performance Month-12.34% Performance Quart-22.67% Performance Half-20.84%
Performance Year14.08% Performance Year-to-date-2.99% Volatility daily3.08% Volatility weekly6.89%
Volatility monthly14.12% Volatility yearly48.92% Relative Volume366.28% Average Volume534.07 K
New High New Low


2019-03-12 01:34:48 | Edited Transcript of DRNA earnings conference call or presentation 11-Mar-19 8:30pm GMT

2019-03-11 21:28:07 | Dicerna Pharmaceuticals Inc DRNA Q4 2018 Earnings Conference Call Transcript

2019-03-11 17:35:09 | Dicerna Pharmaceuticals DRNA Reports Q4 Loss, Lags Revenue Estimates

2019-03-11 16:42:22 | Dicerna Pharmaceuticals: 4Q Earnings Snapshot

2019-03-11 16:05:00 | Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update

2019-03-11 14:30:00 | Dicerna Pharmaceuticals, Inc. to Host Earnings Call

2019-03-06 08:30:00 | New Research: Key Drivers of Growth for Energy Transfer LP, Domo, Accenture, Chevron, Cincinnati Financial, and Dicerna Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2019-03-04 16:05:00 | Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019

2019-03-01 16:30:00 | Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-02-22 16:49:00 | Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

2019-02-21 09:10:00 | ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth

2019-02-12 13:17:00 | Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer

2019-02-05 07:35:00 | Recent Analysis Shows DICK'S Sporting Goods, Zix, Q2, InfraREIT, The Boston Beer, and Dicerna Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-01 16:30:00 | Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-01-28 07:30:00 | Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus

2019-01-24 07:30:00 | Dicerna Evolves Its Board of Directors to Support Continued Growth

2019-01-08 16:05:00 | Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-01-04 07:00:00 | Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna

2018-12-20 07:30:00 | Dicerna to Join NASDAQ Biotechnology Index

2018-12-19 07:30:00 | Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company

2018-12-15 23:06:44 | Here is What Hedge Funds Think About Dicerna Pharmaceuticals Inc DRNA

2018-11-30 07:45:00 | Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-29 07:30:00 | Dicerna to Participate in Citi’s 2018 Global Healthcare Conference

2018-11-28 13:05:22 | Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

2018-11-26 11:33:36 | Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date

2018-11-09 08:00:00 | Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018

2018-11-06 07:30:00 | Dicerna to Participate in Upcoming Investor Conferences

2018-11-06 01:25:27 | Edited Transcript of DRNA earnings conference call or presentation 5-Nov-18 9:30pm GMT

2018-11-05 18:40:11 | Dicerna Pharmaceuticals DRNA Reports Q3 Loss, Misses Revenue Estimates

2018-11-05 17:36:32 | Dicerna Pharmaceuticals: 3Q Earnings Snapshot

2018-11-05 16:05:00 | Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update

2018-11-01 09:55:00 | 3 Pharma Stocks to Make a Portfolio Feel Better

2018-10-31 14:08:06 | Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

2018-10-30 07:30:00 | Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018

2018-10-29 09:31:30 | Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal

2018-10-29 07:09:00 | Dicerna's stock rockets after licensing, research collaboration with Eli Lilly

2018-10-29 06:00:00 | Eli Lilly makes bet on gene-silencing drug firm Dicerna

2018-10-29 06:00:00 | Lilly and Dicerna Announce RNAi Licensing and Research Collaboration

2018-10-29 06:00:00 | Drug giant Lilly backs Cambridge's Dicerna in $200M deal

2018-10-25 13:00:00 | Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 PH1 and PH2

2018-10-24 23:28:41 | Alexion Pharmaceuticals Inc ALXN Q3 2018 Earnings Conference Call Transcript

2018-10-24 16:41:01 | Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue

2018-10-24 10:46:50 | Alexion enters RNA gene-silencing field with $637M Dicerna deal

2018-10-24 07:49:00 | Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance

2018-10-24 06:30:00 | Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases

2018-10-23 08:25:00 | New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-10-05 12:54:00 | Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018

2018-09-24 07:30:00 | Dicerna to Participate in Two Upcoming Investor Conferences

2018-09-14 10:24:12 | Why Dicerna Pharmaceuticals Stock Rose 7.7% Yesterday

2018-09-12 18:00:41 | Bluebird Bio Stock May Have Upside of at Least 60 Percent